Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of coronary artery disease on clinical outcomes after TAVR: Insights from the BRAVO-3 randomized trial.
Feldman D, Cao D, Sartori S, Zhang Z, Hengstenberg C, Tron C, Anthopoulos P, Widder JD, Meneveau N, Stella PR, Ferrari M, Jeger R, Violini R, Dumonteil N, Chen S, Yan R, Nicolas J, Razuk V, Spirito A, Vogel B, Mehran R, Dangas G. Feldman D, et al. Among authors: violini r. Catheter Cardiovasc Interv. 2023 May;101(6):1134-1143. doi: 10.1002/ccd.30647. Epub 2023 Apr 10. Catheter Cardiovasc Interv. 2023. PMID: 37036268 Clinical Trial.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
[GISE (Italian Society of Interventional Cardiology) Position paper: Short-term hospitalization for percutaneous coronary intervention; a helpful tool to manage post-COVID-19 backlogs].
Violini R, De Rosa S, Leonardi S, Doronzo B, Cremonesi A, Callea G, Spandonaro F, Tarantini G, Esposito G, Cernetti C, Indolfi C, Berti S, Marchese A, Saia F, Monti F. Violini R, et al. G Ital Cardiol (Rome). 2021 Dec;22(12 Suppl 2):4-15. doi: 10.1714/3723.37134. G Ital Cardiol (Rome). 2021. PMID: 35343485 Italian.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial.
Razuk V, Camaj A, Cao D, Nicolas J, Hengstenberg C, Sartori S, Zhang Z, Power D, Beerkens F, Chiarito M, Meneveau N, Tron C, Dumonteil N, Widder JD, Ferrari M, Violini R, Stella PR, Jeger R, Anthopoulos P, Mehran R, Dangas GD. Razuk V, et al. Among authors: violini r. Catheter Cardiovasc Interv. 2021 Nov 15;98(6):E870-E880. doi: 10.1002/ccd.29753. Epub 2021 May 12. Catheter Cardiovasc Interv. 2021. PMID: 33909348 Clinical Trial.
Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial.
Zilberszac R, Chandiramani R, Hengstenberg C, Sartori S, Cao D, Chandrasekhar J, Schafer U, Tchetche D, Violini R, Jeger R, Van Belle E, Boekstegers P, Hambrecht R, Tron C, Dumenteil N, Linke A, Ten Berg JM, Deliargyris EN, Anthopoulos P, Mehran R, Dangas G. Zilberszac R, et al. Among authors: violini r. Catheter Cardiovasc Interv. 2020 Sep 1;96(3):E377-E386. doi: 10.1002/ccd.28642. Epub 2019 Dec 5. Catheter Cardiovasc Interv. 2020. PMID: 31808295 Free PMC article.
Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction.
Chichareon P, Modolo R, Collet C, Tenekecioglu E, Vink MA, Oh PC, Ahn JM, Musto C, Díaz de la Llera LS, Cho YS, Violini R, Park SJ, Suryapranata H, Piek JJ, de Winter RJ, Wykrzykowska JJ, Spaulding C, Kang WC, Slagboom T, Hofma SH, Wijnbergen IF, Di Lorenzo E, Pijls NH, Räber L, Brugaletta S, Sabaté M, Stoll HP, Stone GW, Windecker S, Onuma Y, Serruys PW. Chichareon P, et al. Among authors: violini r. J Am Coll Cardiol. 2019 Nov 26;74(21):2572-2584. doi: 10.1016/j.jacc.2019.09.038. J Am Coll Cardiol. 2019. PMID: 31753202 Free article.
Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial.
Goel R, Power D, Tchetche D, Chandiramani R, Guedeney P, Claessen BE, Sartori S, Cao D, Meneveau N, Tron C, Dumonteil N, Widder JD, Hengstenberg C, Ferrari M, Violini R, Stella PR, Jeger R, Anthopoulos P, Deliargyris EN, Mehran R, Dangas GD. Goel R, et al. Among authors: violini r. Int J Cardiol. 2019 Dec 15;297:22-29. doi: 10.1016/j.ijcard.2019.09.063. Epub 2019 Oct 11. Int J Cardiol. 2019. PMID: 31630816 Clinical Trial.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
131 results